文献速递慢性静脉疾病静脉血栓栓塞

静脉支架治疗髂静脉与腔静脉闭塞性疾病的系统综述

A systematic review of venous stents for iliac and venacaval occlusive disease.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2019-11-05

该系统综述纳入2005年至2018年发表的23项研究和2项全国性报告,共3812条置入支架的肢体。专用静脉支架用于740例患者,标准支架用于3072例患者。总体主要并发症率低于1%,标准支架的中位症状改善率和溃疡愈合率分别为79%和71%,专用静脉支架12个月总体一期通畅率为78.8%。

要点

  • 髂腔静脉支架治疗慢性静脉疾病安全有效,主要并发症率低于1%。
  • 标准支架中位一期、辅助一期和二期通畅率分别为71%、89%和91%。
  • 专用静脉支架12个月一期通畅率78.8%,血栓后病变更低(73%)而压迫性病变较高(96%)。

核心结论

  • 尽管证据质量仍较弱,髂腔静脉支架置入似乎是治疗慢性静脉疾病安全有效的方法。
  • 早期结果显示专用静脉支架安全,且效果与历史使用器械相当或更好。

研究设计与样本

  • 通过Ovid门户检索MEDLINE数据库,纳入2005年1月1日至2018年12月31日发表的英文随机对照试验和病例系列。
  • 纳入标准为至少30例患者且随访至少6个月,最终分析23项已发表研究和2项全国性报告,共3812条置入支架的肢体。
  • 专用静脉支架用于740例患者,标准支架用于3072例患者。

主要发现

  • 总体主要并发症率低于1%。
  • 标准支架置入肢体的中位症状改善率为79%,溃疡愈合率为71%。
  • 标准支架的中位一期、辅助一期和二期通畅率分别为71%、89%和91%,中位研究随访23.5个月。
  • 专用静脉支架12个月总体一期通畅率为78.8%,血栓后疾病通畅率(73%)低于压迫性疾病(96%)。

临床怎么用

  • 对于慢性静脉疾病,髂腔静脉支架置入可作为安全有效的治疗选择。
  • 专用静脉支架的早期结果与标准支架相当或更优,可考虑用于适宜患者。

局限性

  • 相关研究异质性太大,无法进行正式荟萃分析。
  • 证据质量仍较弱。
  • 纳入的研究中包含可能尚未正式发表的全国性报告结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endovascular stenting of the deep venous system is increasingly used to treat stenotic and occluded veins. This article reviews the efficacy and safety of venous stenting for lower extremity occlusive disease. METHODS: The Ovid portal was used to search the MEDLINE database for English-language randomized controlled trials and case series published between January 1, 2005, and December 31, 2018, involving venous stenting for lower extremity and inferior venacaval occlusive and compressive disease. Studies were eligible for inclusion if they contained at least 30 patients with at least 6 months of follow-up. Clinical outcomes, long-term patency, complications, and postoperative anticoagulation regimens were reviewed. Also included are nationally presented trial results of dedicated venous stents that may not have been formally published yet. RESULTS: Relevant studies were too heterogeneous for a formal meta-analysis to be performed. We analyzed 3812 stented limbs from 23 published studies and two national presentations. Dedicated venous stents were used in 740 patients, and standard stents were used in 3072 patients. The overall major complication rate was <1%. Median symptomatic improvement and ulcer healing were seen in 79% and 71% of the standard stented limbs, respectively. For standard stents, the median primary, assisted primary, and secondary patency rates were 71%, 89%, and 91%, respectively, with a median study follow-up of 23.5 months. Dedicated venous stents had an overall primary patency of 78.8% at 12 months, with lower patency (73%) seen in post-thrombotic vs compressive (96%) disease. CONCLUSIONS: Whereas the quality of evidence remains weak, iliocaval venous stenting appears to be a safe and effective treatment of chronic venous disease. In early results, dedicated venous stents appear safe and demonstrate results that are as good as or better than those of historically used devices.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Williams ZF, Dillavou ED. A systematic review of venous stents for iliac and venacaval occlusive disease. J Vasc Surg Venous Lymphat Disord. 2019. PMID: 31699668. doi:10.1016/j.jvsv.2019.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。